Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 53 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/22/2008 First Published: 7/1/1999


1.		Phase II/III Study of Standard and Novel Conditioning Therapy and Allogeneic Blood or Marrow Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 to 70				Other				RPCI-RP-9815 NCI-V99-1527, NCT00003816, RP 98-15

Last Modified: 5/14/2007 First Published: 11/1/2002


2.		Phase I/II Study of Immunologically Engineered, Filgrastim (G-CSF)-Mobilized, Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia Transformed From MDS, or Myeloproliferative Disorders

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 65				NCI				FHCRC-1628.00 NCI-H02-0099, NCT00049634

Last Modified: 1/29/2008 First Published: 10/21/2005


3.		Phase I/II Study of Nonmyeloablative Conditioning Comprising Busulfan, Fludarabine, and Total-Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 75				NCI				OHSU-HEM-05011-L OHSU-210, NCT00245037

Last Modified: 5/15/2007 First Published: 3/2/2007


4.		Phase I/II Study of Cyclophosphamide and Busulfan Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Idiopathic Myelofibrosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				65 and under				NCI				FHCRC-2130.00 NCT00445744


5.		Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Lymphoproliferative Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				PDX-009 NCT00481871


6.		Phase I, Open-Label, Dose-Escalation, Safety and Pharmacokinetics (PK) Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				D2782C00007 NCT00486265

Last Modified: 7/28/2008 First Published: 8/14/2007


7.		Phase I/II Randomized Pilot Study of Targeted Immune-Depleting Chemotherapy, Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation from an HLA-Matched Unrelated Donor, and Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus, Methotrexate, and Sirolimus Versus Alemtuxumab and Cyclosporine in Patients With High-Risk Advanced Hematologic Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 to 69				NCI				NCI-07-C-0195 07-C-0195, NCT00520130

Last Modified: 5/22/2008 First Published: 12/11/2007


8.		Phase I/II Study of Conditioning Regimen Comprising Clofarabine, Melphalan, and Alemtuzumab Followed By Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				75 and under				NCI				UCCRC-14341B 14341B, UCCRC-05-155, NCT00572546

Last Modified: 9/29/2008 First Published: 2/26/2008


9.		Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				Other				BCM-H-19386 BCM-FAB, H 19386, NCT00625144

Last Modified: 9/29/2008 First Published: 1/11/2008


10.		Phase I/II Pilot Study of a Nonmyeloablative Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, Fludarabine Phosphate , and Low-Dose Total-Body Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-Risk Hematological Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				Under 100				Other				BCM-H-12472 H 12472, BCM-ACHE, NCT00056966

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute